Key result
Non-vitamin K antagonist oral anticoagulants significantly reduced the risk of stroke or systemic embolic events compared to warfarin (RR 0.81, p<0.0001) in patients with atrial fibrillation.
Why the study?
Do non-vitamin K antagonist oral anticoagulants reduce stroke or systemic embolic events compared to warfarin in patients with atrial fibrillation?
Population
Patients with atrial fibrillation at risk of stroke
Comparison
Non-vitamin K antagonist oral anticoagulants… vs Warfarin
Design
Review
Authors
Loading...
Supports NOAC preference over warfarin in AF; leaves open edoxaban ICH benefits pending higher-certainty trials.
Do non-vitamin K antagonist oral anticoagulants reduce stroke or systemic embolic events compared to warfarin in patients with atrial fibrillation?
Relative Risk: 0.81
p-value: p=<0.0001
NOACs, particularly edoxaban, provide effective stroke prevention in atrial fibrillation while significantly reducing the risk of major bleeding and intracranial hemorrhage compared to warfarin.
Kelly et al. (2016) conducted a review in Atrial fibrillation (n=71,683). Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Warfarin was evaluated on Stroke or systemic embolic events (RR 0.81, p=<0.0001). Non-vitamin K antagonist oral anticoagulants significantly reduced the risk of stroke or systemic embolic events compared to warfarin (RR 0.81, p<0.0001) in patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: